Skip to main content

Search

Reset all filters
948 Result(s)
Sort by

Patient Documentary

Patient Documentary

People with type 2 diabetes are two to four times more likely to develop heart disease compared with people without diabetes
weBuy

weBuy

Supplier Information: WeBuy is a key initiative in order to have an integrated solution for the Source to Procure Process around the globe.
Oncology

Oncology

We are looking for new early-science collaborations and invite you to join our expanding community of innovation partners in oncology.
Our transformative team culture

Our transformative team culture

The immunology team is grounded in three key elements: Curiosity, creativity and courage. Hear about the culture at Boehringer Ingelheim.
Collaborating for social impact

Collaborating for social impact

Societal challenges require collective action and Making More Health Together is connecting changemakers to drive collaborations for more social impact
Transforming Science Day Europe

Transforming Science Day Europe

Oct. 2, 2023: Join us in London, or virtually, to learn more about our patient-centric approach to innovation, advancing pipeline and partnering approach.
Avian influenza prevention at the source

Avian influenza prevention at the source

Teshome Mebatsion, Head of Viral Diseases Research at Boehringer Ingelheim, talks about the avian influenza virus, ways of prevention and scenarios for the future.
Brigitte Fuhr

Brigitte Fuhr

Brigitte Fuhr, our Head of Central Data Science, joined our team to make millions of lives better. Now she’s working on a global program that will transform our ability to develop ground-breaking treatments.
garbage game

garbage game

Learn more about marine pollution and find out how long it takes for garbage to dissolve in the oceans.
Respiratory Diseases

Respiratory Diseases

We are looking for new early-science collaborations and invite you to join our expanding community of innovation partners in respiratory diseases.
Our Vision

Our Vision

At Boehringer Ingelheim, we have expanded our global research and development activities to tackle eye diseases, specifically those affecting the back of the eye.
EASi-HF™ Phase III trial in patients with HFpEF

EASi-HF™ Phase III trial in patients with HFpEF

Boehringer Ingelheim's Sandy Sommer on the global urgency for innovative heart failure care and the significance of the clinical trial for patients with HFpEF worldwide.